The novel compound (±)-1-[10-((E)-3-Phenyl-allyl)-3,10-diaza-bicyclo[4.3.1]dec-3-yl]-propan-1-one (NS7051) attenuates nociceptive transmission in animal models of experimental pain; a pharmacological comparison with the combined μ-opioid receptor agonist and monoamine reuptake inhibitor tramadol

Neuropharmacology

Volumn 54, Issue 2, 2008, Pages 331-343

  Munro, Gordon ^a   Bæk, Camilla Æ ^a   Erichsen, Helle K ^a   Nielsen, Alexander N ^a   Nielsen, Elsebet Ø ^a   Scheel Kruger, Jørgen ^a   Weikop, Pia ^a   Peters, Dan ^a  

^a NEUROSEARCH A S   (Denmark)

Author keywords

Analgesia; Antidepressant; Central sensitization; Formalin test; Inflammatory pain; Neuropathic pain

Indexed keywords

1 [10 (3 PHENYL ALLYL) 3,10 DIAZA BICYCLO[4.3.1]DEC 3 YL] PROPAN 1 ONE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; BENZATROPINE; BRAIN MONOAMINE; DESIPRAMINE; DOPAMINE; DULOXETINE; FORMALDEHYDE; FREUND ADJUVANT; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NALOXONE; NORADRENALIN; NS 7051; OPIATE ANTAGONIST; SEROTONIN; TRAMADOL; UNCLASSIFIED DRUG; VENLAFAXINE; YOHIMBINE; 1 (10 ((E) 3 PHENYL ALLYL) 3,10 DIAZA BICYCLO(4.3.1)DEC 3 YL)PROPAN 1 ONE; 1-(10-((E)-3-PHENYL-ALLYL)-3,10-DIAZA-BICYCLO(4.3.1)DEC-3-YL)PROPAN-1-ONE; AZABICYCLO DERIVATIVE; DELTA OPIATE RECEPTOR; DIAGNOSTIC AGENT; NARCOTIC ANALGESIC AGENT; NEUROTRANSMITTER UPTAKE INHIBITOR;

ALLODYNIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATAXIA; BRAIN CORTEX; CHRONIC INFLAMMATION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TISSUE LEVEL; EXPERIMENTAL TEST; HIPPOCAMPUS; HOT PLATE TEST; HYPERALGESIA; IN VITRO STUDY; MALE; MICRODIALYSIS; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PERIPHERAL NERVE INJURY; PRIORITY JOURNAL; ROTAROD TEST; TAIL FLICK TEST; ANIMAL; BODY EQUILIBRIUM; BRAIN; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; INFLAMMATION; METABOLISM; NOCICEPTIVE RECEPTOR; PAIN; PAIN ASSESSMENT; PSYCHOLOGICAL ASPECT; RAT; REACTION TIME; SPRAGUE DAWLEY RAT; SYNAPTIC TRANSMISSION;

ANALGESICS, OPIOID; ANIMALS; AZABICYCLO COMPOUNDS; BEHAVIOR, ANIMAL; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FORMALDEHYDE; FREUND'S ADJUVANT; INFLAMMATION; MALE; MICRODIALYSIS; MUSCULOSKELETAL EQUILIBRIUM; NEUROTRANSMITTER UPTAKE INHIBITORS; NOCICEPTORS; PAIN; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; SYNAPTIC TRANSMISSION; TRAMADOL;

EID: 38148999379     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.10.005     Document Type: Article

References (44)

1. Apaydin S., Uyar M., Karabay N.U., Erhan E., Yegul I., and Tuglular I. The antinociceptive effect of tramadol on a model of neuropathic pain in rats. Life Sciences 66 (2000) 1627-1637
2. Bennett G.J., and Xie Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33 (1988) 87-107
3. Bian D., Nichols M.L., Ossipov M.H., Lai J., and Porreca F. Characterization of the antiallodynic efficacy of morphine in a model of neuropathic pain in rats. Neuroreport 6 (1995) 1981-1984
4. Bomholt S.F., Mikkelsen J.D., and Blackburn-Munro G. Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. Neuropharmacology 48 (2005) 252-263
5. Coderre T.J., Katz J., Vaccarino A.L., and Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain 52 (1993) 259-285
6. de Pozos-Guillen A.J., Aguirre-Banuelos P., Arellano-Guerrero A., Hoyo-Vadillo C., and Perez-Urizar J. Evidence of self-synergism in the antinociceptive effect of tramadol in rats. Proceedings of the Western Pharmacological Society 47 (2004) 117-119
7. Erichsen H.K., Hao J.X., Xu X.J., and Blackburn-Munro G. Comparative actions of the opioid analgesics morphine, methadone and codeine in rat models of peripheral and central neuropathic pain. Pain 116 (2005) 347-358
8. Furlan A.D., Sandoval J.A., Mailis-Gagnon A., and Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 174 (2006) 1589-1594
9. Franklin K.B., and Abbott F.V. Pentobarbital, diazepam, and ethanol abolish the interphase diminution of pain in the formalin test: evidence for pain modulation by GABAA receptors. Pharmacology Biochemistry and Behaviour 46 (1993) 661-666
10. Garrido M.J., Valle M., Campanero M.A., Calvo R., and Troconiz I.F. Modeling of the in vivo antinociceptive interaction between an opioid agonist, (+)-O-desmethyltramadol, and a monoamine reuptake inhibitor, (-)-O-desmethyltramadol, in rats. Journal of Pharmacology and Experimental Therapeutics 295 (2000) 352-359
11. Gillen C., Haurand M., Kobelt D.J., and Wnendt S. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Archives of Pharmacology 362 (2000) 116-121
12. Gimbel J.S., Richards P., and Portenoy R.K. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 60 (2003) 927-934
13. Granados-Soto V., and Arguelles C.F. Synergic antinociceptive interaction between tramadol and gabapentin after local, spinal and systemic administration. Pharmacology 74 (2005) 200-208
14. Grond S., and Sablotzki A. Clinical pharmacology of tramadol. Clinical Pharmacokinetics 43 (2004) 879-923
15. Henry J.L., Yashpal K., Pitcher G.M., and Coderre T.J. Physiological evidence that the 'interphase' in the formalin test is due to active inhibition. Pain 82 (1999) 57-63
16. Hopwood S.E., Owesson C.A., Callado L.F., McLaughlin D.P., and Stamford J.A. Effects of chronic tramadol on pre- and post-synaptic measures of monoamine function. Journal of Psychopharmacology 15 (2001) 147-153
17. Kayser V., Besson J.M., and Guilbaud G. Evidence for a noradrenergic component in the antinociceptive effect of the analgesic agent tramadol in an animal model of clinical pain, the arthritic rat. European Journal of Pharmacology 224 (1992) 83-88
18. Le Bars D., Gozariu M., and Cadden S.W. Animal models of nociception. Pharmacological Reviews 53 (2001) 597-652
19. Leventhal L., Smith V., Hornby G., Andree T.H., Brandt M.R., and Rogers K.E. Differential and synergistic effects of selective norepinephrine and serotonin reuptake inhibitors in rodent models of pain. Journal of Pharmacology and Experimental Therapeutics 320 (2007) 1178-1185
20. Lindner M.D., Plone M.A., Francis J.M., and Cain C.K. Chronic morphine reduces pain-related disability in a rodent model of chronic, inflammatory pain. Experimental and Clinical Psychopharmacology 7 (1999) 187-197
21. Maguire P., Tsai N., Kamal J., Cometta-Morini C., Upton C., and Loew G. Pharmacological profiles of fentanyl analogs at mu, delta and kappa opiate receptors. European Journal of Pharmacology 213 (1992) 219-225
22. Markowitz J.S., and Patrick K.S. Venlafaxine-tramadol similarities. Medical Hypotheses 51 (1998) 167-168
23. Mattia C., and Coluzzi F. Tramadol. Focus on musculoskeletal and neuropathic pain. Minerva Anestesiologica 71 (2005) 565-584
24. Millan M.J. Descending control of pain. Progress in Neurobiology 66 (2002) 355-474
25. Munro G. Dopamine D1 and D2 receptor agonism enhances antinociception mediated by the serotonin and noradrenaline reuptake inhibitor duloxetine in the rat formalin test. European Journal of Pharmacology 575 (2007) 66-74
26. Oliva P., Aurilio C., Massimo F., Grella A., Maione S., Grella E., Scafuro M., Rossi F., and Berrino L. The antinociceptive effect of tramadol in the formalin test is mediated by the serotonergic component. European Journal of Pharmacology 445 (2002) 179-185
27. Ossipov M.H., Lopez Y., Nichols M.L., Bian D., and Porreca F. Inhibition by spinal morphine of the tail-flick response is attenuated in rats with nerve ligation injury. Neuroscience Letters 199 (1995) 83-86
28. Paxinos G., and Watson C. The Rat Brain. Stereotaxic Coordinates. Compact third ed. (1997), Academic Press Inc., CA, USA
29. Pedersen L.H., Nielsen A.N., and Blackburn-Munro G. Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain. Psychopharmacology 182 (2005) 551-561
30. Porreca F., Ossipov M.H., and Gebhart G.F. Chronic pain and medullary descending facilitation. Trends in Neurosciences 25 (2002) 319-325
31. Raffa R.B., Friderichs E., Reimann W., Shank R.P., Codd E.E., and Vaught J.L. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. Journal of Pharmacology and Experimental Therapeutics 260 (1992) 275-285
32. Raffa R.B., Friderichs E., Reimann W., Shank R.P., Codd E.E., Vaught J.L., Jacoby H.I., and Selve N. Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. Journal of Pharmacology and Experimental Therapeutics 267 (1993) 331-340
33. Raja S.N., Haythornthwaite J.A., Pappagallo M., Clark M.R., Travison T.G., Sabeen S., Royall R.M., and Max M.B. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 59 (2002) 1015-1021
34. Rode F., Broløs T., Blackburn-Munro G., and Bjerrum O.J. Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain. Psychopharmacology 187 (2006) 364-375
35. Rojas-Corrales M.O., Ortega-Alvaro A., Gibert-Rahola J., Roca-Vinardell A., and Mico J.A. Pindolol, a beta-adrenoceptor blocker/5-hydroxytryptamine(1A/1B) antagonist, enhances the analgesic effect of tramadol. Pain 88 (2000) 119-124
36. Simonin F., Befort K., Gaveriaux-Ruff C., Matthes H., Nappey V., Lannes B., Micheletti G., and Kieffer B. The human delta-opioid receptor: genomic organization, cDNA cloning, functional expression, and distribution in human brain. Molecular Pharmacology 46 (1994) 1015-1021
37. Sindrup S.H., Otto M., Finnerup N.B., and Jensen T.S. Antidepressants in the treatment of neuropathic pain. Basic & Clinical Pharmacology & Toxicology 96 (2005) 399-409
38. Suzuki R., Rygh L.J., and Dickenson A.H. Bad news from the brain: descending 5-HT pathways that control spinal pain processing. Trends in Pharmacological Sciences 25 (2004) 613-617
39. Wang J.B., Johnson P.S., Persico A.M., Hawkins A.L., Griffin C.A., and Uhl G.R. Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Letters 338 (1994) 217-222
40. Weikop P., Kehr J., and Scheel-Kruger J. The role of alpha1- and alpha2-adrenoreceptors on venlafaxine-induced elevation of extracellular serotonin, noradrenaline and dopamine levels in the rat prefrontal cortex and hippocampus. Journal of Psychopharmacology 18 (2004) 395-403
41. Whiteside G.T., Boulet J.M., and Walker K. The role of central and peripheral mu opioid receptors in inflammatory pain and edema: a study using morphine and DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid). Journal of Pharmacology and Experimental Therapeutics 314 (2005) 1234-1240
42. Wilson A.W., Medhurst S.J., Dixon C.I., Bontoft N.C., Winyard L.A., Brackenborough K.T., De Alba J., Clarke C.J., Gunthorpe M.J., Hicks G.A., Bountra C., McQueen D.S., and Chessell I.P. An animal model of chronic inflammatory pain: pharmacological and temporal differentiation from acute models. European Journal of Pain 10 (2006) 537-549
43. Yaksh T.L., Ozaki G., McCumber D., Rathbun M., Svensson C., Malkmus S., and Yaksh M.C. An automated flinch detecting system for use in the formalin nociceptive bioassay. Journal of Applied Physiology 90 (2001) 2386-2402
44. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16 (1983) 109-110